Divi's Laboratories Ltd

Divi's Lab. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Divi's Laboratories Ltd

₹ 3,719 0.08%
16 Apr 11:02 a.m.
divislaboratories.com BSE: 532488 NSE : DIVISLAB
About

Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients[1]

Key Points

Business Overview:[1]
Company manufactures Generic Active pharmaceuticals ingredients, Custom synthesis of APIs & Intermediates along with Nutraceuticals for Global Pharmaceutical & Nutraceutical industry. These are segmented as:
a) Generic APIs:[2]
Company manufactures 30 Large Volume Generic APIs in 10’s to 100’s/1000’s of Tons each year and exports them to 100+ countries. Further, there are 10 APIs in various stages of R&D and pilot scale development
b) Custom Synthesis:[3]
Company under Custom Synthesis of APIs and Intermediates for global companies with a portfolio of products across diverse therapeutic areas. 12 out of top 20 Big Pharma Companies across US, EU and Japan have been associated with Divi’s for 10+ years
c) Nutraceutical:[4][5]
Company's Vishakhapatnam unit produces active ingredient and finished forms of Carotenoids. It is currently supplying carotenoids to all major food, dietary supplement and feed manufacturers globally. Company also offers customized ingredient solutions in liquids, beadlets and powder forms

Website BSE NSE
  • Market Cap ₹ 98,737 Cr.
  • Current Price ₹ 3,719
  • High / Low ₹ 4,074 / 3,050
  • Stock P/E 72.4
  • Book Value ₹ 475
  • Dividend Yield 0.82 %
  • ROCE 19.3 %
  • ROE 14.8 %
  • Face Value ₹ 2.00
Edit ratios

Pros

  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 32.7%

Cons

  • Stock is trading at 7.83 times its book value

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs

Edit Columns
Loading peers table ...

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Dec 2020 Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
1,656 1,718 1,950 1,968 2,467 2,495 2,204 1,823 1,690 1,908 1,730 1,868 1,808
978 1,019 1,099 1,149 1,367 1,399 1,367 1,214 1,280 1,419 1,239 1,394 1,317
Operating Profit 678 699 851 819 1,100 1,096 837 609 409 489 491 474 491
OPM % 41% 41% 44% 42% 45% 44% 38% 33% 24% 26% 28% 25% 27%
20 23 36 19 17 51 90 79 116 66 80 85 94
Interest 0 0 0 0 0 0 0 0 0 0 0 1 0
Depreciation 68 70 73 77 80 81 83 85 87 87 93 94 95
Profit before tax 630 652 814 760 1,037 1,066 844 603 439 468 478 464 490
Tax % 27% 25% 32% 20% 12% 17% 18% 19% 29% 32% 28% 26% 27%
461 488 552 606 907 883 691 487 311 319 345 342 358
EPS in Rs 17.37 18.38 20.79 22.84 34.17 33.26 26.03 18.34 11.71 12.02 13.00 12.88 13.49
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 TTM
1,845 2,129 2,514 3,084 3,720 4,024 3,816 4,880 5,311 6,799 8,880 7,625 7,314
1,149 1,306 1,492 1,914 2,314 2,582 2,558 3,028 3,491 3,971 5,000 5,275 5,369
Operating Profit 696 823 1,022 1,170 1,406 1,441 1,258 1,851 1,820 2,828 3,880 2,350 1,945
OPM % 38% 39% 41% 38% 38% 36% 33% 38% 34% 42% 44% 31% 27%
66 49 81 36 92 73 106 155 187 57 109 348 325
Interest 5 3 3 3 4 3 2 5 7 2 2 2 1
Depreciation 62 77 92 136 118 123 142 169 186 255 311 342 369
Profit before tax 695 792 1,009 1,067 1,375 1,388 1,219 1,833 1,813 2,628 3,677 2,354 1,900
Tax % 21% 23% 22% 21% 19% 24% 29% 27% 24% 26% 20% 23%
546 611 792 847 1,111 1,053 870 1,333 1,373 1,955 2,949 1,808 1,364
EPS in Rs 20.56 23.03 29.82 31.90 41.84 39.68 32.76 50.20 51.71 73.63 111.07 68.11 51.39
Dividend Payout % 32% 33% 34% 31% 24% 25% 31% 32% 31% 27% 27% 44%
Compounded Sales Growth
10 Years: 14%
5 Years: 15%
3 Years: 13%
TTM: -11%
Compounded Profit Growth
10 Years: 11%
5 Years: 16%
3 Years: 11%
TTM: -42%
Stock Price CAGR
10 Years: 19%
5 Years: 17%
3 Years: -1%
1 Year: 18%
Return on Equity
10 Years: 22%
5 Years: 21%
3 Years: 22%
Last Year: 15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Sep 2023
Equity Capital 27 27 27 27 53 53 53 53 53 53 53 53 53
Reserves 2,148 2,527 3,008 3,535 4,304 5,356 5,907 6,920 7,264 9,218 11,638 12,652 12,544
55 33 18 27 42 36 63 106 34 0 0 0 2
573 610 731 886 566 765 785 961 1,164 1,452 1,617 1,646 1,575
Total Liabilities 2,803 3,196 3,784 4,475 4,965 6,210 6,808 8,040 8,514 10,724 13,308 14,352 14,174
738 908 1,222 1,309 1,439 1,559 1,996 2,087 2,776 3,699 4,321 4,719 4,651
CWIP 182 303 144 218 264 444 120 492 920 711 470 212 496
Investments 480 411 505 736 813 1,639 1,897 1,953 979 7 79 84 87
1,403 1,573 1,913 2,212 2,450 2,568 2,795 3,508 3,839 6,307 8,438 9,337 8,940
Total Assets 2,803 3,196 3,784 4,475 4,965 6,210 6,808 8,040 8,514 10,724 13,308 14,352 14,174

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
334 483 558 822 1,036 1,149 765 964 1,208 1,947 1,910 2,448
-204 -254 -305 -521 -411 -1,137 -476 -684 -81 75 -2,195 -2,707
-131 -231 -248 -303 -630 3 -314 -246 -1,091 -34 -532 -797
Net Cash Flow -1 -2 5 -1 -5 15 -25 34 36 1,988 -817 -1,055

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2012 Mar 2013 Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Debtor Days 106 96 115 97 95 91 106 96 105 94 106 94
Inventory Days 307 369 355 335 284 291 311 324 299 322 316 329
Days Payable 74 72 59 67 56 103 98 94 99 118 92 88
Cash Conversion Cycle 339 392 411 365 323 280 319 325 305 298 330 335
Working Capital Days 149 156 165 149 169 156 191 181 186 155 178 190
ROCE % 34% 33% 36% 32% 35% 28% 21% 28% 24% 32% 35% 19%

Shareholding Pattern

Numbers in percentages

8 Recently
Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024
51.95% 51.95% 51.95% 51.94% 51.94% 51.94% 51.94% 51.94% 51.93% 51.93% 51.92% 51.92%
20.60% 20.70% 19.30% 18.45% 16.52% 15.40% 15.15% 14.67% 14.69% 14.60% 14.85% 14.68%
16.56% 16.36% 17.73% 18.32% 19.98% 20.75% 20.62% 21.00% 21.15% 21.65% 21.78% 22.10%
0.00% 0.00% 0.00% 0.00% 0.00% 0.03% 0.05% 0.07% 0.10% 0.10% 0.10% 0.10%
10.89% 11.00% 11.02% 11.28% 11.56% 11.88% 12.23% 12.31% 12.13% 11.72% 11.33% 11.19%
No. of Shareholders 1,93,8832,23,4032,74,5053,09,3973,46,9053,79,2574,14,8474,33,6214,02,1553,73,8603,54,4823,47,630

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls